Skip to content

Celcuity CELC Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Gilead Sciences logo
Gilead SciencesGILD
$7.63B-3.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$882.02M+62.5%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$204.59M+119%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$241.21M+91.4%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$159.97M+162%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's cash & equivalents?
Celcuity (CELC) reported cash & equivalents of $145.19M in Q1 2026.
How has Celcuity's cash & equivalents changed year-over-year?
Celcuity's cash & equivalents increased by 781.1% year-over-year, from $16.48M to $145.19M.
What is the long-term trend for Celcuity's cash & equivalents?
Over 5 years (2020 to 2025), Celcuity's cash & equivalents has grown at a 102.5% compound annual growth rate (CAGR), from $11.38M to $387.1M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.